Perampanel Oral Suspension + Perampanel Tablet

Phase 2Recruiting
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pediatric Epileptic Syndrome

Conditions

Pediatric Epileptic Syndrome, Partial-onset Seizures

Trial Timeline

May 31, 2019 → Dec 23, 2027

About Perampanel Oral Suspension + Perampanel Tablet

Perampanel Oral Suspension + Perampanel Tablet is a phase 2 stage product being developed by Eisai for Pediatric Epileptic Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04015141. Target conditions include Pediatric Epileptic Syndrome, Partial-onset Seizures.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04015141Phase 2Recruiting